Rexulti On Track To Add Claim For Alzheimer’s Dementia Agitation Following US Panel Nod

 
• By Sue Sutter
  
Path in forest
Rexulti is on a path to becoming the first FDA-approved treatment for agitation associated with Alzheimer's dementia. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers